{
  "schema_version": "uw.editorial_geo.v1",
  "representation_profile": "lossless_source_sections",
  "local_stage_only": true,
  "catalog_id": "DEP-11-N06",
  "article_index": "DEP-11-N06",
  "language": "en",
  "headline": "Medication treatment for opioid dependence",
  "description": "Medication treatment for opioid dependence",
  "short_answer": "Opioid use disorder can return after a short period of improvement, and a return can have severe consequences. The question “Why is treatment lasting so long?” therefore deserves a discussion about benefit, safety, and the person's freedom to choose. Continuing suitable care may protect health. The length of a prescription alone proves neither a new dependence on a clinician nor the integrity of a particular service.\n\nIf an opioid overdose is suspected, breathing is impaired, or a person cannot be awakened, contact the local emergency service immediately. If authorised naloxone is available and an opioid overdose is suspected, follow the instructions for that product or the dispatcher's directions. Stay with the person until help arrives; if it is safe and consistent with the dispatcher's directions, turn them onto their side to reduce the risk of choking. The [FDA](https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose) stresses that naloxone's effect is temporary and further medical help is needed even if the person wakes up. It is for opioid overdose and does not address every possible cause of a serious condition. When there are threats or violence, the person at risk needs separate protection and local help, regardless of the other person's treatment.",
  "short_answer_source": {
    "kind": "opening_after_h1",
    "role": "lead",
    "start_utf16": 46,
    "end_utf16": 1367,
    "sha256_utf8": "7f1f6eb32cf8145cf672b645686986a3030c4376d2f10d79c067d293abfa295d"
  },
  "headline_source": {
    "role": "h1_heading",
    "start_utf16": 2,
    "end_utf16": 44,
    "sha256_utf8": "b13b77c99cb5ba5dca01e87ad0a07605b3b0d2a0ad07f30db8f5b7fb05590381"
  },
  "entities": [],
  "questions": [
    {
      "q": "I. What medication is meant to do",
      "a": "The [CDC](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html) describes three medication options for opioid use disorder in the United States: methadone, buprenorphine, and naltrexone. Methadone and buprenorphine are forms of agonist treatment, although they act differently; naltrexone is an antagonist. These differences matter for selection, assessment, and safety. A US list does not establish that all three options are authorised, available, or covered in every country.\n\nSuitable treatment aims to reduce dangerous use and serious harms while allowing a person to rebuild daily life and remain connected with care. A prescription by itself promises none of those outcomes. The clinician and patient can review actual changes, adverse effects, other conditions, interactions, preferences, and the conditions for obtaining medication. Physical adaptation to prescribed medication, possible difficulty stopping it, and a substance use disorder are distinct questions. It is inaccurate to call every long course of treatment “one addiction replaced by another” without that assessment; it is also inaccurate to declare it risk-free for everyone.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 1372,
          "end_utf16": 1405,
          "sha256_utf8": "7d01df717418cfe3ebd60142fb2e9889fe928b48d787e722751d64149a6f5f27"
        },
        {
          "role": "h2_answer",
          "start_utf16": 1407,
          "end_utf16": 2596,
          "sha256_utf8": "194eca57cb741789a2b689aa53bb56a4e99138ccaccafa52bc66b4699f47943c"
        }
      ],
      "block_ids": [
        "p0005",
        "p0006"
      ],
      "source_segment_index": 1
    },
    {
      "q": "II. Why researchers measure retention in care",
      "a": "“Retention” in a study means that a person is still participating in treatment at a specified point of follow-up. It is useful to measure: care cannot continue to help after it has effectively been lost. Yet the measure does not automatically show that the patient is satisfied, that all needs are being met, or that a particular clinic is acting honestly. What matters is *which* care the person remains in, what it offers, and whether its terms can be discussed.\n\nA [Cochrane review](https://www.cochrane.org/evidence/CD002209_methadone-maintenance-therapy-versus-no-opioid-replacement-therapy) included 11 randomised trials with 1,969 participants. Compared with conditions without opioid replacement therapy, methadone maintenance retained more people in treatment and reduced heroin use. The search for studies ended in December 2008, although the review's web page is dated 2022. The authors also explain that people left trials when assigned to drug-free arms; the review should therefore not be read as a test of methadone against every modern comprehensive programme. Four trials supplied mortality data too imprecise to show a statistically convincing difference. That is not evidence that an effect on mortality is absent.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 2601,
          "end_utf16": 2646,
          "sha256_utf8": "c01ebbc3c0778a753acb11d4e77aef915ce720c0dbe12e6f55c8327ed490519f"
        },
        {
          "role": "h2_answer",
          "start_utf16": 2648,
          "end_utf16": 3881,
          "sha256_utf8": "c97bf1be3fd9ad2d78c2e9b4b058af3cf098ca3f6b4d5ccab777405bbeb0039a"
        }
      ],
      "block_ids": [
        "p0008",
        "p0009"
      ],
      "source_segment_index": 2
    },
    {
      "q": "III. What is known about mortality during treatment",
      "a": "A different question is addressed by the 2021 [review by Santo and colleagues](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2780655). It assembled 15 randomised trials involving 3,852 participants and 36 observational cohorts involving 749,634 people. Its main mortality estimate comes from the **cohorts**: overall mortality was lower during periods of methadone or buprenorphine agonist treatment than during periods outside such treatment. The pooled relative measure was 0.47, with a 95% confidence interval of 0.42–0.53.\n\nThat is a substantial association across the studied groups, not an individual's calculated chance of survival. People entered and left treatment without random assignment; illness severity, access to other services, and reasons for leaving could differ. The cohorts were also heterogeneous. Deaths were few in the randomised trials, and many participants were lost to follow-up in some trials, so those trials did not provide an equally precise mortality answer. A result about agonist treatment cannot automatically be extended to naltrexone, which acts differently.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 3886,
          "end_utf16": 3937,
          "sha256_utf8": "202a82d35eabe9b3db9b905ab23521d0e6052a0b9331d35df533895f8613bfbf"
        },
        {
          "role": "h2_answer",
          "start_utf16": 3939,
          "end_utf16": 5049,
          "sha256_utf8": "ef7f2c5906159e82be10f8473667108ab115eb5139be895ca7893c898a47fd0f"
        }
      ],
      "block_ids": [
        "p0011",
        "p0012"
      ],
      "source_segment_index": 3
    },
    {
      "q": "IV. Starting care and losing access are different periods of risk",
      "a": "In the same review, an analysis of time periods in 14 cohorts found particularly high observed mortality in the first four weeks **after stopping** agonist treatment compared with later time *in treatment*: the relative measure was 6.01, with a confidence interval of 4.32–8.36. Risk near the start of methadone treatment also differed from risk later in treatment. These findings support careful clinical safety and continuity of care; they are not a calendar for a reader to start or stop medication.\n\nPeople leave a programme for many reasons, including unsuitable conditions, a move, adverse effects, loss of coverage, or their own decision. An observational association does not prove that a particular departure itself caused a particular death. But stopping treatment and loss of opioid tolerance can increase overdose danger if opioid use resumes. Do not change or stop a prescription by following an article: discuss a plan for changes, monitoring, and safety with a qualified clinician, especially when access is already being disrupted.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 5054,
          "end_utf16": 5119,
          "sha256_utf8": "917fe9fb20f7fcdc7221ac530a513bff5d9e6e65c42b09c23bead9a5a389941b"
        },
        {
          "role": "h2_answer",
          "start_utf16": 5121,
          "end_utf16": 6168,
          "sha256_utf8": "ac2cf5eb0c272947134fdb8ce9d89241607d22d82ade7a978898cedace2b11fc"
        }
      ],
      "block_ids": [
        "p0014",
        "p0015"
      ],
      "source_segment_index": 4
    },
    {
      "q": "V. Detoxification and continuing support",
      "a": "Short-term medical management of withdrawal and continuing treatment afterwards address different needs. The [CDC clinical page](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html) warns against detoxification alone without subsequent medication treatment for opioid use disorder because return to use, overdose, and death remain risks. This does not mean everyone needs the same medication or duration; it does mean that subsequent support deserves discussion with a qualified clinician.\n\nPsychological, social, and housing support can be valuable parts of recovery. According to the CDC, their absence in a particular setting, or a person's decision not to use psychosocial services now, should not delay access to medication treatment. Perfect motivation, an already discovered purpose in life, or a promise of complete abstinence is not an entry requirement for a first conversation about medical care.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 6173,
          "end_utf16": 6213,
          "sha256_utf8": "3281b32d15f60977ccbe8c3e91fb209721db305ac2d76ad92a70c63eb2922abd"
        },
        {
          "role": "h2_answer",
          "start_utf16": 6215,
          "end_utf16": 7162,
          "sha256_utf8": "1cfc1fa9746359bcbd308c1d2a8861285dd590a8a38dc0413069f3e7cc154734"
        }
      ],
      "block_ids": [
        "p0017",
        "p0018"
      ],
      "source_segment_index": 5
    },
    {
      "q": "VI. Is there a correct end date?",
      "a": "In the specific opioid use disorder section of the [CDC's 2022 guideline](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm), there is no recommended fixed duration limit for buprenorphine, methadone, or naltrexone treatment. The guideline as a whole concerns opioid prescribing for pain; only its opioid use disorder section is used here. The absence of a general limit means duration is considered in light of a person's condition and results, not an arbitrary calendar. It does not oblige everyone to stay in treatment forever.\n\nA review can consider what has actually changed: dangerous use, overdoses, sleep, work or housing, the ability to attend care, adverse effects, and personal goals. A clinician can explain why they suggest continuing, changing, or completing a form of care and how safety would be supported through change. A patient can ask questions and seek another qualified opinion. Discussing duration does not require stopping medication independently or testing whether one can “manage without it.”",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 7167,
          "end_utf16": 7199,
          "sha256_utf8": "2baa47b9d1628b946643152d94378545c9dc622877df27ffcae6796a7c7f5072"
        },
        {
          "role": "h2_answer",
          "start_utf16": 7201,
          "end_utf16": 8223,
          "sha256_utf8": "e9c0dc6bfdd8ffbdce3befb29eefd3189c562ae1be9ca4d0d9bfce67da520148"
        }
      ],
      "block_ids": [
        "p0020",
        "p0021"
      ],
      "source_segment_index": 6
    },
    {
      "q": "VII. Duration of treatment and trust in a clinic",
      "a": "Retention in suitable, voluntary care is a desirable outcome when it brings real benefit. It does not authorise a service to coerce a person, hide its terms, or ignore concerns. Equally, a long course of treatment alone does not prove “commercial retention.” An allegation of misconduct by a particular service requires separate verifiable evidence about its actions, terms, and timing; mortality research does not establish such a finding about any clinic.\n\nA person may ask for a clear explanation of a medication's purpose, the criteria for reviewing it, known risks, and available alternatives. If answers remain unclear or trust has been lost, another opinion and help with a transition can be discussed without an abrupt break in care. Someone supporting the patient can help find a contact with the adult's consent, but cannot make the medical decision for them and is not obliged to pay for treatment or endure threats.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 8228,
          "end_utf16": 8276,
          "sha256_utf8": "342baa2f58bdac3d375833b8116fd1237cc67d0d3370d7a33012128f60316d55"
        },
        {
          "role": "h2_answer",
          "start_utf16": 8278,
          "end_utf16": 9205,
          "sha256_utf8": "19bd5ed2a264aa9125e25cd74d44a0b0dcd0b70112b999fc1d3ca8d505c2425a"
        }
      ],
      "block_ids": [
        "p0023",
        "p0024"
      ],
      "source_segment_index": 7
    },
    {
      "q": "VIII. Access in practice",
      "a": "The CDC and FDA pages describe the US context. Elsewhere, authorised medicines, age rules, costs, language, privacy rules, and waiting times can differ. It is useful to ask a local service whether it is taking new patients, what happens before the first actual appointment, and who can help if access is interrupted. Joining a waiting list is not the same as receiving care; rising risk calls for a more urgent local assessment.\n\nIf someone is already receiving treatment, requesting a review should not turn into a demand to prove “willpower” by stopping medication. Overdose danger calls for the emergency route at the start of this article. Protection for a person experiencing violence is separate even when the other person's treatment continues. Children do not become monitors of adults' use, custodians of their medicines, or the people responsible for dispensing them.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 9210,
          "end_utf16": 9234,
          "sha256_utf8": "4a7d72f9b4cc14074ae3089666055dbe236bb5a0cc838ec37ffd57df4a1ce81c"
        },
        {
          "role": "h2_answer",
          "start_utf16": 9236,
          "end_utf16": 10113,
          "sha256_utf8": "43cc7ddeaf37d9f78e47fa8d1376d31b645336d6e8e21f0d9824e908e1711b19"
        }
      ],
      "block_ids": [
        "p0026",
        "p0027"
      ],
      "source_segment_index": 8
    },
    {
      "q": "IX. Using this information in a conversation",
      "a": "A concrete question for a clinician is: what benefits and difficulties can we see now, what is known about the risk of interrupting this care, and which changes can we safely discuss? The answer might involve continuing treatment, changing support, or a planned transition. Research gives reasons to take continuity seriously, but does not replace consent or individual assessment. The conversation can begin before a person is certain of their final goal.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 10118,
          "end_utf16": 10162,
          "sha256_utf8": "1114966a774b6f8a0bd2eb203ce5e8798d0c6bf759f6f9c3a10d82f0214b8a7f"
        },
        {
          "role": "h2_answer",
          "start_utf16": 10164,
          "end_utf16": 10620,
          "sha256_utf8": "7ad23f46d93c1aefc0244bf67f37f8e61fbe897014c07645505c304b818ac9f8"
        }
      ],
      "block_ids": [
        "p0029"
      ],
      "source_segment_index": 9
    },
    {
      "q": "Appendix: five optional points before seeking help",
      "a": "These original questions concern only what a person already knows. They are not a test, a treatment schedule, or a condition for receiving care. Any item may be skipped. Suspected overdose, impaired breathing, or another immediate danger calls for local emergency help first; violence calls for separate protection.\n\n1. What benefit from current care has the person noticed, and what difficulty do they want to discuss?\n2. What does current support include beyond receiving medication, and what is missing?\n3. Is it already known whom to contact if prescribed care changes or access is interrupted?\n4. Which real conditions of a local service—admission, waiting time, cost, language, and privacy—have been checked?\n5. Who can help organise urgent safety with the adult's consent without shifting medical decisions to relatives or children?\n\nNot having answers does not remove anyone's right to ask for help.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 10625,
          "end_utf16": 10675,
          "sha256_utf8": "6b94726d399257c229093182334b578ec4a37113a87f72de808596384c619089"
        },
        {
          "role": "h2_answer",
          "start_utf16": 10677,
          "end_utf16": 11584,
          "sha256_utf8": "0870290e46b3612562a4b7bdcfc60df7b78371faf73c819bdd997956e2c2aee5"
        }
      ],
      "block_ids": [
        "p0031",
        "p0032",
        "p0033"
      ],
      "source_segment_index": 10
    },
    {
      "q": "Sources and limits",
      "a": "1. Mattick R. P. et al. [*Methadone maintenance therapy versus no opioid replacement therapy*](https://www.cochrane.org/evidence/CD002209_methadone-maintenance-therapy-versus-no-opioid-replacement-therapy). Official Cochrane summary, page dated 1 April 2022, study search through December 2008; 11 randomised trials, 1,969 participants. The full review and individual trials were not read.\n2. Santo T. Jr. et al. [*Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence*](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2780655). *JAMA Psychiatry*, 2021; original publisher HTML of a review of randomised trials and observational cohorts. The observational association does not establish causation for an individual.\n3. Centers for Disease Control and Prevention. [*Opioid Use Disorder: Treating*](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html). US clinical page dated 9 April 2024; medication options and the limit of detoxification without subsequent care. It does not establish availability elsewhere.\n4. Centers for Disease Control and Prevention. [*CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022*](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm). Only the section on opioid use disorder and treatment duration is used; pain-prescribing details were not transferred here.\n5. U.S. Food and Drug Administration. [*Access to Naloxone Can Save a Life During an Opioid Overdose*](https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose). Official page; no publication date shown on the page read, checked 14 October 2026. First aid does not replace local emergency medical care.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 11589,
          "end_utf16": 11607,
          "sha256_utf8": "f91f16500d95114ea5dd62762b302ab95f247ca4f49fe0affb04993b09f0a299"
        },
        {
          "role": "h2_answer",
          "start_utf16": 11609,
          "end_utf16": 13408,
          "sha256_utf8": "3b1224b896db1a5571a84548f8329f7bb57ed331feccb93672667414483d0a31"
        }
      ],
      "block_ids": [
        "p0035"
      ],
      "source_segment_index": 11
    },
    {
      "q": "Topics",
      "a": "opioid use disorder; medication treatment; methadone; buprenorphine; naltrexone; retention in care; mortality; detoxification; naloxone; consent; safety; access.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 13413,
          "end_utf16": 13419,
          "sha256_utf8": "e22820fcf5cd90e3fdd99a7569e0ee2f30eb7ebadfb2fe4d159b30c166ff81b7"
        },
        {
          "role": "h2_answer",
          "start_utf16": 13421,
          "end_utf16": 13582,
          "sha256_utf8": "50ed8b4bc3c09a51140b352cffc3735422a2e10a2e5486b5f72b213feeebe732"
        }
      ],
      "block_ids": [
        "p0037"
      ],
      "source_segment_index": 12
    },
    {
      "q": "Authors",
      "a": "Andrey Zarinsh — author and founder of United Wisdom. He explores inner transformation, the unity of traditions, intercultural dialogue, and contemporary spiritual discipline. Instagram: @andrey.zarinsh.\n\nMaria Evilkut — co-author of United Wisdom. Alongside her research, she seeks to test these ideas in practice and observe how the principles of unity and mutual understanding work in real life between people and cultures. Instagram: @ilkutki.\n\nContent reviewed: 14 October 2026. Language version: EN.",
      "source_spans": [
        {
          "role": "h2_heading",
          "start_utf16": 13587,
          "end_utf16": 13594,
          "sha256_utf8": "2c00c9aaa72c717ad6d901a09c4d698a68b2e9740be3769e0af7d6bd85d72d5d"
        },
        {
          "role": "h2_answer",
          "start_utf16": 13596,
          "end_utf16": 14101,
          "sha256_utf8": "ab7d0cd6f69436ae5b0a9015b0793ae2f264c3970ecc7712187345104806b594"
        }
      ],
      "block_ids": [
        "p0039",
        "p0040",
        "p0041"
      ],
      "source_segment_index": 13
    }
  ],
  "claims": [],
  "claims_policy": "no_reclassified_claims",
  "sources": [
    {
      "id": "src_1c2951f63465fbee",
      "title": "*Access to Naloxone Can Save a Life During an Opioid Overdose*",
      "url": "https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose",
      "source_spans": [
        {
          "role": "markdown_link",
          "start_utf16": 919,
          "end_utf16": 1025,
          "sha256_utf8": "0cf7e75c1c13403f21b829a2dff1b167e584452fcb0a1a0909d97f6315fba992"
        },
        {
          "role": "markdown_link",
          "start_utf16": 13101,
          "end_utf16": 13266,
          "sha256_utf8": "6c2320e17b488b25f029d62cda392d1c6573a801bad5e36c6a1d28008a8ef66d"
        }
      ],
      "read_scope": "5. U.S. Food and Drug Administration. [*Access to Naloxone Can Save a Life During an Opioid Overdose*](https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose). Official page; no publication date shown on the page read, checked 14 October 2026. First aid does not replace local emergency medical care.",
      "read_scope_kind": "verbatim_bibliography_entry",
      "read_scope_span": {
        "role": "bibliography_entry",
        "start_utf16": 13063,
        "end_utf16": 13408,
        "sha256_utf8": "c56202f3d8f5d46d7cc836cc7a0a79d0ca63801c9d8fe05e900ac4b02fbf42dd"
      },
      "shared_entry_urls": []
    },
    {
      "id": "src_d7a377a386f6456c",
      "title": "*Opioid Use Disorder: Treating*",
      "url": "https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html",
      "source_spans": [
        {
          "role": "markdown_link",
          "start_utf16": 1411,
          "end_utf16": 1509,
          "sha256_utf8": "9eb102f740d85f8abfb44c701275e4342099a777951ce8935d5688cadb020690"
        },
        {
          "role": "markdown_link",
          "start_utf16": 6324,
          "end_utf16": 6436,
          "sha256_utf8": "1002c665b47d72421e648e3e9cc1c2220a40bd4de123a9d207c1905b6f7ce005"
        },
        {
          "role": "markdown_link",
          "start_utf16": 12460,
          "end_utf16": 12586,
          "sha256_utf8": "de06aba4bcfcf31d4ef8af8d51183295490e257e3348af877cb10b0428db29e0"
        }
      ],
      "read_scope": "3. Centers for Disease Control and Prevention. [*Opioid Use Disorder: Treating*](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html). US clinical page dated 9 April 2024; medication options and the limit of detoxification without subsequent care. It does not establish availability elsewhere.",
      "read_scope_kind": "verbatim_bibliography_entry",
      "read_scope_span": {
        "role": "bibliography_entry",
        "start_utf16": 12413,
        "end_utf16": 12746,
        "sha256_utf8": "a8d0d87b4aa1c9a88abbfa473d6bc5153b1478325d9093e0478f30a26ad1e87e"
      },
      "shared_entry_urls": []
    },
    {
      "id": "src_35e912001dfca457",
      "title": "*Methadone maintenance therapy versus no opioid replacement therapy*",
      "url": "https://www.cochrane.org/evidence/CD002209_methadone-maintenance-therapy-versus-no-opioid-replacement-therapy",
      "source_spans": [
        {
          "role": "markdown_link",
          "start_utf16": 3116,
          "end_utf16": 3244,
          "sha256_utf8": "55a22d94514d11068f8332ebc0488fa8f60efc2e470dfff3d907342183def25e"
        },
        {
          "role": "markdown_link",
          "start_utf16": 11633,
          "end_utf16": 11814,
          "sha256_utf8": "3e46b3a758b21fed06745e25d8c2e820df1a2f92cb4beff3fecd172140593e3f"
        }
      ],
      "read_scope": "1. Mattick R. P. et al. [*Methadone maintenance therapy versus no opioid replacement therapy*](https://www.cochrane.org/evidence/CD002209_methadone-maintenance-therapy-versus-no-opioid-replacement-therapy). Official Cochrane summary, page dated 1 April 2022, study search through December 2008; 11 randomised trials, 1,969 participants. The full review and individual trials were not read.",
      "read_scope_kind": "verbatim_bibliography_entry",
      "read_scope_span": {
        "role": "bibliography_entry",
        "start_utf16": 11609,
        "end_utf16": 11998,
        "sha256_utf8": "2fde60a04d156dbe79149549a0deb8d4ba27816b07d8e2cb634c01de6109abcc"
      },
      "shared_entry_urls": []
    },
    {
      "id": "src_f7e76a36ac7ac1be",
      "title": "*Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence*",
      "url": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2780655",
      "source_spans": [
        {
          "role": "markdown_link",
          "start_utf16": 3985,
          "end_utf16": 4086,
          "sha256_utf8": "f2616a8451893d5ca13a9bfee7a7ba70e0015264991959927a1d3cb4395fd4c3"
        },
        {
          "role": "markdown_link",
          "start_utf16": 12022,
          "end_utf16": 12224,
          "sha256_utf8": "bf50a298b8ac10f26f8ca6bc8187c7772e403d5c71a9cb5527999eb2f23f3cc3"
        }
      ],
      "read_scope": "2. Santo T. Jr. et al. [*Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence*](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2780655). *JAMA Psychiatry*, 2021; original publisher HTML of a review of randomised trials and observational cohorts. The observational association does not establish causation for an individual.",
      "read_scope_kind": "verbatim_bibliography_entry",
      "read_scope_span": {
        "role": "bibliography_entry",
        "start_utf16": 11999,
        "end_utf16": 12412,
        "sha256_utf8": "b551db75a5558ad2ea6d590b96c73cbeaffe30b8c71a944f80ea683779c62e08"
      },
      "shared_entry_urls": []
    },
    {
      "id": "src_ede712eaefe50ff2",
      "title": "*CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022*",
      "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm",
      "source_spans": [
        {
          "role": "markdown_link",
          "start_utf16": 7252,
          "end_utf16": 7327,
          "sha256_utf8": "3552047712e0a1d063ae48406961250a9679ef8a3cd5a751f58052d9edd2e309"
        },
        {
          "role": "markdown_link",
          "start_utf16": 12794,
          "end_utf16": 12937,
          "sha256_utf8": "50752016bd445418fd6e1d9834de6eb93412615f56cd19db7437fb90c7e75720"
        }
      ],
      "read_scope": "4. Centers for Disease Control and Prevention. [*CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022*](https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm). Only the section on opioid use disorder and treatment duration is used; pain-prescribing details were not transferred here.",
      "read_scope_kind": "verbatim_bibliography_entry",
      "read_scope_span": {
        "role": "bibliography_entry",
        "start_utf16": 12747,
        "end_utf16": 13062,
        "sha256_utf8": "1765d6faa0695bf2d832be90fe98a5e3d2fb4284f02db8300154286685931dad"
      },
      "shared_entry_urls": []
    }
  ],
  "retrieval_limits": [
    "This local GEO representation applies only to the specified source article version and its SHA-256.",
    "Qualifications, sources and attributions remain in the full sections and byte-identical Markdown copy.",
    "No new source research was conducted in this GEO stage."
  ],
  "master_sha256": "13995274bae73cce95e8bc3410597790aeb4f9198b178b175ac1cf46e4ebe95f",
  "provenance": {
    "raw_reader_sha256": "13995274bae73cce95e8bc3410597790aeb4f9198b178b175ac1cf46e4ebe95f",
    "ru_master_sha256": "201df6a94a61a9c3f0279000098839f806fbbb6d7a77a79d058c0c868654d9d2",
    "reader_path": "outputs/uw-addictions-corpus-20261013/articles/DEP-11-N06/ARTICLE_EN.md",
    "review_pointer": "outputs/uw-addictions-corpus-20261013/articles/DEP-11-N06/INDEPENDENT_REVIEW.json",
    "review_sha256": "85edb18da0a167555adeaa8f20ce31d952fd31293205b7c79aebd9715a950a89",
    "clean_md_relative_filename": "GEO.en.md",
    "body_length_utf16": 14102,
    "source_segments": [
      {
        "kind": "opening",
        "index": 0,
        "heading": null,
        "start_utf16": 0,
        "end_utf16": 1369,
        "sha256_utf8_raw_slice": "2db71502da23d078052d302367ee931c3b439165e9f3c16cfcfe14fbce91239d"
      },
      {
        "kind": "h2_section",
        "index": 1,
        "heading": "I. What medication is meant to do",
        "start_utf16": 1369,
        "end_utf16": 2598,
        "sha256_utf8_raw_slice": "6287c06d98a6fce42ba26e3bf8a4d70e2596c727fcf1d7e806d2853de348dce5"
      },
      {
        "kind": "h2_section",
        "index": 2,
        "heading": "II. Why researchers measure retention in care",
        "start_utf16": 2598,
        "end_utf16": 3883,
        "sha256_utf8_raw_slice": "697d17a053f05c18080191e7ffe9770016ba391b5a9eb9990d348493025e3553"
      },
      {
        "kind": "h2_section",
        "index": 3,
        "heading": "III. What is known about mortality during treatment",
        "start_utf16": 3883,
        "end_utf16": 5051,
        "sha256_utf8_raw_slice": "1d74913d1414541531199952700d950f0b906218832dc77aa7d1d2dd0620496b"
      },
      {
        "kind": "h2_section",
        "index": 4,
        "heading": "IV. Starting care and losing access are different periods of risk",
        "start_utf16": 5051,
        "end_utf16": 6170,
        "sha256_utf8_raw_slice": "d0b8c61462c58ac3d8e357a9663a08ebdbb26e5e377c74c7dd22753cbe6e7508"
      },
      {
        "kind": "h2_section",
        "index": 5,
        "heading": "V. Detoxification and continuing support",
        "start_utf16": 6170,
        "end_utf16": 7164,
        "sha256_utf8_raw_slice": "6f37d75e45a8f9a8b90d1b73cd85e2a4180ff180939ba005b4c2716d2064b90d"
      },
      {
        "kind": "h2_section",
        "index": 6,
        "heading": "VI. Is there a correct end date?",
        "start_utf16": 7164,
        "end_utf16": 8225,
        "sha256_utf8_raw_slice": "57eff880fc3d9df8cb91ed899467490ce0cc8d92f752e3d8179ffb382af487d4"
      },
      {
        "kind": "h2_section",
        "index": 7,
        "heading": "VII. Duration of treatment and trust in a clinic",
        "start_utf16": 8225,
        "end_utf16": 9207,
        "sha256_utf8_raw_slice": "fdc132368c609470d5f229b70aeba909df8811cf5095f9f73a558b164f107b51"
      },
      {
        "kind": "h2_section",
        "index": 8,
        "heading": "VIII. Access in practice",
        "start_utf16": 9207,
        "end_utf16": 10115,
        "sha256_utf8_raw_slice": "69eba1d13b13193175f7b169535c4e4b9a0e06d502c416a5cb0bf39180323575"
      },
      {
        "kind": "h2_section",
        "index": 9,
        "heading": "IX. Using this information in a conversation",
        "start_utf16": 10115,
        "end_utf16": 10622,
        "sha256_utf8_raw_slice": "ec91213b04e77eedd2661f957316dad57af139c7e9f1d779e5c89b0dc3c2b799"
      },
      {
        "kind": "h2_section",
        "index": 10,
        "heading": "Appendix: five optional points before seeking help",
        "start_utf16": 10622,
        "end_utf16": 11586,
        "sha256_utf8_raw_slice": "72d34abb6647b24e0b6f2c3d0090fd062c89e45198a6434bd5481d1572e8a103"
      },
      {
        "kind": "h2_section",
        "index": 11,
        "heading": "Sources and limits",
        "start_utf16": 11586,
        "end_utf16": 13410,
        "sha256_utf8_raw_slice": "23f6cb64c71f62a1187e41427fbf2f83a4076af54bc768d93bbcecf2adf82cd3"
      },
      {
        "kind": "h2_section",
        "index": 12,
        "heading": "Topics",
        "start_utf16": 13410,
        "end_utf16": 13584,
        "sha256_utf8_raw_slice": "c50f3bb3fcb44abf7280328e346e0012dfbcc57062d5d46795020904b065fa51"
      },
      {
        "kind": "h2_section",
        "index": 13,
        "heading": "Authors",
        "start_utf16": 13584,
        "end_utf16": 14102,
        "sha256_utf8_raw_slice": "9c9b236dfafc227deab2ff99d53bd94d35901244feec4ec6c493b6797155088e"
      }
    ],
    "common_blocks_module_sha256": "6cf638661a819f960c39d08058bf6d0d0696e8b816f677d95b389f5f1d11e4d2"
  }
}